Focus: GT Biopharma is a public biotech company focused on antioxidant therapeutics and antibodies across metabolic diseases and oncology, operating since 1999 from San Francisco.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow GT Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead commercial asset in Phase 3/4 for glioblastoma with potential near-term label expansion; represents company's highest clinical validation
Help build intelligence for GT Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GT Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Minimally invasive surgical device platform with multiple obesity/metabolic indications; clinical maturity and regulatory pathway unclear
Early-stage T-cell engaging immunotherapy representing company's entry into cell therapy; 1 active Phase 1/2 trial
New prostate cancer trial tests NK cell drug for hard-to-treat tumors - Stock Titan
New prostate cancer trial tests NK cell drug for hard-to-treat tumors Stock Titan
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types - Yahoo Finance UK
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types Yahoo Finance UK
GT Biopharma Inc stock (US36254L1098): FDA clears IND for NK cell therapy GTB-5550 in solid tumors - AD HOC NEWS
GT Biopharma Inc stock (US36254L1098): FDA clears IND for NK cell therapy GTB-5550 in solid tumors AD HOC NEWS
The critical factors shaping GT Biopharma (GTBP) future (Softens) 2026-05-08 - Large Cap Trends - newser.com
The critical factors shaping GT Biopharma (GTBP) future (Softens) 2026-05-08 - Large Cap Trends newser.com
GT Biopharma (NASDAQ: GTBP) backs $3.8M GTB-5550 cancer trial pact - Stock Titan
GT Biopharma (NASDAQ: GTBP) backs $3.8M GTB-5550 cancer trial pact Stock Titan
8-K Filing: GT Biopharma, Inc. (GTBP) (CIK 0000109657) — 8-K
8-K
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy.
Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo